2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Victoria Furer*, Christien Rondaan, Marloes W. Heijstek, Nancy Agmon-Levin, Sander Van Assen, Marc Bijl, Ferry C. Breedveld, Raffaele D'amelio, Maxime Dougados, Meliha Crnkic Kapetanovic, Jacob M. Van Laar, A. De Thurah, Robert B.M. Landewé, Anna Molto, Ulf Müller-Ladner, Karen Schreiber, Leo Smolar, Jim Walker, Klaus Warnatz, Nico M. WulffraatOri Elkayam

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

To update the European League Against Rheumatism (EULAR) recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) published in 2011. Four systematic literature reviews were performed regarding the incidence/prevalence of vaccine-preventable infections among patients with AIIRD; efficacy, immunogenicity and safety of vaccines; effect of anti-rheumatic drugs on the response to vaccines; effect of vaccination of household of AIIRDs patients. Subsequently, recommendations were formulated based on the evidence and expert opinion. The updated recommendations comprise six overarching principles and nine recommendations. The former address the need for an annual vaccination status assessment, shared decision-making and timing of vaccination, favouring vaccination during quiescent disease, preferably prior to the initiation of immunosuppression. Non-live vaccines can be safely provided to AIIRD patients regardless of underlying therapy, whereas live-attenuated vaccines may be considered with caution. Influenza and pneumococcal vaccination should be strongly considered for the majority of patients with AIIRD. Tetanus toxoid and human papilloma virus vaccination should be provided to AIIRD patients as recommended for the general population. Hepatitis A, hepatitis B and herpes zoster vaccination should be administered to AIIRD patients at risk. Immunocompetent household members of patients with AIIRD should receive vaccines according to national guidelines, except for the oral poliomyelitis vaccine. Live-attenuated vaccines should be avoided during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy. These 2019 EULAR recommendations provide an up-to-date guidance on the management of vaccinations in patients with AIIRD.

OriginalsprogEngelsk
TidsskriftAnnals of the rheumatic diseases
Vol/bind79
Udgave nummer1
Sider (fra-til)39-52
ISSN0003-4967
DOI
StatusUdgivet - jan. 2020

Fingeraftryk

Rheumatic Diseases
Vaccines
Attenuated Vaccines
Papillomaviridae
Tetanus Toxoid
Antirheumatic Agents
Hepatitis A
Herpes Zoster
Expert Testimony
Biological Products
Hepatitis B
Viruses
Human Influenza
Decision making
Mothers
Newborn Infant
Guidelines
Safety
Incidence
Population

Citer dette

Furer, Victoria ; Rondaan, Christien ; Heijstek, Marloes W. ; Agmon-Levin, Nancy ; Van Assen, Sander ; Bijl, Marc ; Breedveld, Ferry C. ; D'amelio, Raffaele ; Dougados, Maxime ; Kapetanovic, Meliha Crnkic ; Van Laar, Jacob M. ; De Thurah, A. ; Landewé, Robert B.M. ; Molto, Anna ; Müller-Ladner, Ulf ; Schreiber, Karen ; Smolar, Leo ; Walker, Jim ; Warnatz, Klaus ; Wulffraat, Nico M. ; Elkayam, Ori. / 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. I: Annals of the rheumatic diseases. 2020 ; Bind 79, Nr. 1. s. 39-52.
@article{b1b9773a076b4f739fe324296c9ce20c,
title = "2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases",
abstract = "To update the European League Against Rheumatism (EULAR) recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) published in 2011. Four systematic literature reviews were performed regarding the incidence/prevalence of vaccine-preventable infections among patients with AIIRD; efficacy, immunogenicity and safety of vaccines; effect of anti-rheumatic drugs on the response to vaccines; effect of vaccination of household of AIIRDs patients. Subsequently, recommendations were formulated based on the evidence and expert opinion. The updated recommendations comprise six overarching principles and nine recommendations. The former address the need for an annual vaccination status assessment, shared decision-making and timing of vaccination, favouring vaccination during quiescent disease, preferably prior to the initiation of immunosuppression. Non-live vaccines can be safely provided to AIIRD patients regardless of underlying therapy, whereas live-attenuated vaccines may be considered with caution. Influenza and pneumococcal vaccination should be strongly considered for the majority of patients with AIIRD. Tetanus toxoid and human papilloma virus vaccination should be provided to AIIRD patients as recommended for the general population. Hepatitis A, hepatitis B and herpes zoster vaccination should be administered to AIIRD patients at risk. Immunocompetent household members of patients with AIIRD should receive vaccines according to national guidelines, except for the oral poliomyelitis vaccine. Live-attenuated vaccines should be avoided during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy. These 2019 EULAR recommendations provide an up-to-date guidance on the management of vaccinations in patients with AIIRD.",
keywords = "autoimmune diseases, infections, vaccination",
author = "Victoria Furer and Christien Rondaan and Heijstek, {Marloes W.} and Nancy Agmon-Levin and {Van Assen}, Sander and Marc Bijl and Breedveld, {Ferry C.} and Raffaele D'amelio and Maxime Dougados and Kapetanovic, {Meliha Crnkic} and {Van Laar}, {Jacob M.} and {De Thurah}, A. and Landew{\'e}, {Robert B.M.} and Anna Molto and Ulf M{\"u}ller-Ladner and Karen Schreiber and Leo Smolar and Jim Walker and Klaus Warnatz and Wulffraat, {Nico M.} and Ori Elkayam",
year = "2020",
month = "1",
doi = "10.1136/annrheumdis-2019-215882",
language = "English",
volume = "79",
pages = "39--52",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "B M J Group",
number = "1",

}

Furer, V, Rondaan, C, Heijstek, MW, Agmon-Levin, N, Van Assen, S, Bijl, M, Breedveld, FC, D'amelio, R, Dougados, M, Kapetanovic, MC, Van Laar, JM, De Thurah, A, Landewé, RBM, Molto, A, Müller-Ladner, U, Schreiber, K, Smolar, L, Walker, J, Warnatz, K, Wulffraat, NM & Elkayam, O 2020, '2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases', Annals of the rheumatic diseases, bind 79, nr. 1, s. 39-52. https://doi.org/10.1136/annrheumdis-2019-215882

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. / Furer, Victoria; Rondaan, Christien; Heijstek, Marloes W.; Agmon-Levin, Nancy; Van Assen, Sander; Bijl, Marc; Breedveld, Ferry C.; D'amelio, Raffaele; Dougados, Maxime; Kapetanovic, Meliha Crnkic; Van Laar, Jacob M.; De Thurah, A.; Landewé, Robert B.M.; Molto, Anna; Müller-Ladner, Ulf; Schreiber, Karen; Smolar, Leo; Walker, Jim; Warnatz, Klaus; Wulffraat, Nico M.; Elkayam, Ori.

I: Annals of the rheumatic diseases, Bind 79, Nr. 1, 01.2020, s. 39-52.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

AU - Furer, Victoria

AU - Rondaan, Christien

AU - Heijstek, Marloes W.

AU - Agmon-Levin, Nancy

AU - Van Assen, Sander

AU - Bijl, Marc

AU - Breedveld, Ferry C.

AU - D'amelio, Raffaele

AU - Dougados, Maxime

AU - Kapetanovic, Meliha Crnkic

AU - Van Laar, Jacob M.

AU - De Thurah, A.

AU - Landewé, Robert B.M.

AU - Molto, Anna

AU - Müller-Ladner, Ulf

AU - Schreiber, Karen

AU - Smolar, Leo

AU - Walker, Jim

AU - Warnatz, Klaus

AU - Wulffraat, Nico M.

AU - Elkayam, Ori

PY - 2020/1

Y1 - 2020/1

N2 - To update the European League Against Rheumatism (EULAR) recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) published in 2011. Four systematic literature reviews were performed regarding the incidence/prevalence of vaccine-preventable infections among patients with AIIRD; efficacy, immunogenicity and safety of vaccines; effect of anti-rheumatic drugs on the response to vaccines; effect of vaccination of household of AIIRDs patients. Subsequently, recommendations were formulated based on the evidence and expert opinion. The updated recommendations comprise six overarching principles and nine recommendations. The former address the need for an annual vaccination status assessment, shared decision-making and timing of vaccination, favouring vaccination during quiescent disease, preferably prior to the initiation of immunosuppression. Non-live vaccines can be safely provided to AIIRD patients regardless of underlying therapy, whereas live-attenuated vaccines may be considered with caution. Influenza and pneumococcal vaccination should be strongly considered for the majority of patients with AIIRD. Tetanus toxoid and human papilloma virus vaccination should be provided to AIIRD patients as recommended for the general population. Hepatitis A, hepatitis B and herpes zoster vaccination should be administered to AIIRD patients at risk. Immunocompetent household members of patients with AIIRD should receive vaccines according to national guidelines, except for the oral poliomyelitis vaccine. Live-attenuated vaccines should be avoided during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy. These 2019 EULAR recommendations provide an up-to-date guidance on the management of vaccinations in patients with AIIRD.

AB - To update the European League Against Rheumatism (EULAR) recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) published in 2011. Four systematic literature reviews were performed regarding the incidence/prevalence of vaccine-preventable infections among patients with AIIRD; efficacy, immunogenicity and safety of vaccines; effect of anti-rheumatic drugs on the response to vaccines; effect of vaccination of household of AIIRDs patients. Subsequently, recommendations were formulated based on the evidence and expert opinion. The updated recommendations comprise six overarching principles and nine recommendations. The former address the need for an annual vaccination status assessment, shared decision-making and timing of vaccination, favouring vaccination during quiescent disease, preferably prior to the initiation of immunosuppression. Non-live vaccines can be safely provided to AIIRD patients regardless of underlying therapy, whereas live-attenuated vaccines may be considered with caution. Influenza and pneumococcal vaccination should be strongly considered for the majority of patients with AIIRD. Tetanus toxoid and human papilloma virus vaccination should be provided to AIIRD patients as recommended for the general population. Hepatitis A, hepatitis B and herpes zoster vaccination should be administered to AIIRD patients at risk. Immunocompetent household members of patients with AIIRD should receive vaccines according to national guidelines, except for the oral poliomyelitis vaccine. Live-attenuated vaccines should be avoided during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy. These 2019 EULAR recommendations provide an up-to-date guidance on the management of vaccinations in patients with AIIRD.

KW - autoimmune diseases

KW - infections

KW - vaccination

U2 - 10.1136/annrheumdis-2019-215882

DO - 10.1136/annrheumdis-2019-215882

M3 - Journal article

C2 - 31413005

AN - SCOPUS:85070953188

VL - 79

SP - 39

EP - 52

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 1

ER -